West Haven pharmaceutical firm NanoViricides announced Tuesday its further progress in developing a drug to help combat the disease outbreaking in Africa.
NanoViricides previously developed anti-Ebola drug candidates that showed the company’s approach was working, but the firm slowed development of the drug to focus on an injectable drug for people hospitalized by the flu.
Because of the Ebola outbreak in Africa, NanoViricides reprioritized development of the drug. Because of new information in how the Ebola virus attacks the body, the firm has redesigned its drug to better treat as a therapeutic against the disease.
Eugene Seymour, the company’s CEO, will present this information Tuesday on the drug development and how it related to the African outbreak at the Rodman and Renshaw Investment Conference in New York City.
